Massachusetts Clinical Trials Report — June 2026

For Massachusetts residents considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. A significant 264 clinical trials across the state are slated to close within the next 90 days, meaning the chance to enroll in these studies is rapidly diminishing. This urgent call to action includes 49 trials that are actively seeking healthy volunteers, offering a unique opportunity to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers, neurological conditions, and cardiovascular health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Prostate cancer (7 trials)
• Breast cancer (6 trials)
• Stroke (5 trials)
• Depression (5 trials)
• Major depressive disorder (4 trials)
• Heart failure (4 trials)
• Alzheimer disease (4 trials)
• Colorectal cancer (4 trials)
• Opioid use disorder (4 trials)

Groundbreaking Research Launches with Massive Scope

This month, Massachusetts is home to the launch of several truly monumental research initiatives, some aiming for participant numbers rarely seen in clinical trials. These studies, particularly from leading academic institutions, are designed to build robust evidence bases that could reshape medical understanding and practice.

• Brigham and Women's Hospital is sponsoring two exceptionally large studies focused on cardiovascular health and diabetes medications. NCT07619495, "Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk," aims to enroll an astounding 120,000 participants. Its companion study, NCT07619508, "Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes," is targeting 100,000 participants. Both trials are building an empirical evidence base for real-world data, seeking to understand how real-world data analyses can be conducted with confidence for various clinical questions.
• Another significant trial, NCT07651761, "Patient-Centered Practical Vaccine Talk For Busy Clinicians," sponsored by the University of Massachusetts, Worcester, plans for 24,500 participants. This pragmatic, cluster randomized trial will assess the effect of an educational intervention for primary care providers on influenza and COVID-19 vaccine uptake among their adult patients.
• For those interested in digital health, Flo Health Inc. is sponsoring NCT07630064, the "Flo Digital Contraceptive Study," which seeks to enroll 3,800 participants to evaluate if the Flo Digital Contraceptive app can effectively prevent unintended pregnancy in women aged 18 and older.
• A notable Phase 3 drug trial, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron for weight management.
• The Dana-Farber Cancer Institute is leading NCT07675967, the "Clonal Hematopoiesis Chemotherapy and Radiation Effects Study," which aims to enroll 5,000 participants. This study seeks to understand how the presence or absence of clonal hematopoiesis influences outcomes in people receiving chemotherapy and radiation for solid cancers.

New Research Opportunities Across Conditions and Interventions

This June, Massachusetts welcomed 59 new clinical trials, a slight decrease from the 70 trials that opened in May 2026, but still offering a wealth of new opportunities. These new studies cover a diverse range of health conditions, with a strong focus on metabolic health and mental well-being. The most common conditions addressed by these new studies include:

• Obesity (5 trials)
• Overweight (5 trials)
• Depression (3 trials)
• Type 2 diabetes mellitus (3 trials)
• Chronic weight management (2 trials)
• Low back pain (2 trials)
• Sickle cell disease (2 trials)
• Sarcoma (2 trials)
• Chronic pain (2 trials)
• Ureteral stents (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 22 of the new studies, followed closely by device trials with 13 new initiatives. Behavioral interventions are also well-represented with 7 new trials, alongside other types of research including biological treatments and a dietary supplement study.

Geographic Reach: Boston Remains a Hub, Other Cities Expand Access

Massachusetts's clinical research landscape continues to be robust, with 3,124 clinical trials currently recruiting across 95 cities and 1,113 research sites statewide. This month, the majority of new research initiatives are concentrated in the Boston metropolitan area, which saw 37 new trials open. However, opportunities are also expanding in other parts of the state, ensuring broader accessibility:

• Waltham (7 new trials)
• New Bedford (3 new trials)
• Methuen (3 new trials)
• Cambridge (3 new trials)
• Worcester (2 new trials)
• Fall River (1 new trial)
• Andover (1 new trial)
• Needham (1 new trial)
• Newton (1 new trial)

This distribution ensures that residents in various regions of Massachusetts have access to cutting-edge research, even as Boston remains a central hub for clinical investigations. Academic institutions continue to play a vital role in the state's research ecosystem, with Massachusetts General Hospital sponsoring 7 of the new trials, followed by Brigham and Women's Hospital with 5, and Dana-Farber Cancer Institute and Boston Children's Hospital each sponsoring 3. Industry sponsors like AstraZeneca and Gasherbrum Bio, Inc. are also driving significant research efforts.

Healthy Volunteers and Diverse Participation Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 59 new trials launched this month, 13 are actively seeking healthy volunteers. Statewide, a total of 388 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Massachusetts are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 10 include children as participants, and 48 include older adults, ensuring that research benefits diverse age groups. Additionally, 2 new trials are specifically designed for female-only participants. This diversity in eligibility helps ensure that new medical advancements are relevant and safe for a wide population.

As we move through June, the focus will remain on the ongoing enrollment in these significant trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Massachusetts.